|Systematic (IUPAC) name|
|(what is this?)|
Pargyline (Eutonyl) is an irreversible non-selective monoamine oxidase (MAO) inhibitor drug (IC50 for MAO-A is 0.01152micromol/L and for MAO-B is 0.00820micromol/L.)   It was brought to market in the US and the UK by Abbott in 1963 as "Eutonyl" as an antihypertensive drug, and was one of several other MAO inhibitors brought to market in the 1960s, along with nialamide, isocarboxazid, phenelzine, and tranylcypromine.:146:60
- Fisar Z, Hroudová J, Raboch J. (2010). "Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers.". Neuro Endocrinol Lett. 31 (5): 645–56. PMID 21200377.
- Murphy DL, Karoum F, Pickar D et al. (1998). "Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline)". J. Neural Transm. Suppl. 52: 39–48. doi:10.1007/978-3-7091-6499-0_5. PMID 9564606.
- Edward Shorter, A historical dictionary of psychiatry. Oxford University Press, Inc 2005. ISBN 0195176685
- William M. Wardell and Louis Lasagna. Regulation Drug Development (Evaluative Studies 21) American Enterprise Institute (1975) ISBN 0844731676
- Council on Drugs New Drugs and Developments in Therapeutics: Pargyline Hydrochloride (Eutonyl) JAMA. 1963;184(11):887. doi:10.1001/jama.1963.03700240079013.
- W. Steven Pray Interactions Between Nonprescription Products and Psychotropic Medications US Pharmacist. 2007;32(11):12-15.
- FDA Eutonyl in the Drugs@FDA Database Accessed July 19, 2014
|This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|